A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin
- PMID: 23864485
- DOI: 10.1007/s10928-013-9326-0
A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin
Abstract
Previous models for predicting tumor cell growth are mostly based on measurements of total cell numbers. The purpose of this paper is to provide a new simple mathematical model for calculating tumor cell growth focusing on the fraction of cells that is clonogenic. The non-clonogenic cells are considered to be relatively harmless. We performed a number of different types of experiments: a long-term drug "treatment", several concentrations/fixed time experiments and time-series experiments, in which human MCF-7 breast cancer cells were exposed to doxorubicin and the total number of cells were counted. In the latter two types, at every measurement point a plating efficiency experiment was started. The final number of colonies formed is equal to the number of clonogenic cells at the onset of the experiment. Based on the intracellular drug concentration, our model predicts cell culture effects taking clonogenic ability and growth inhibition by neighboring cells into account. The model fitted well to the experimental data. The estimated damage parameter which represents the chance of an MCF-7 cell to become non-clonogenic per unit time and per unit intracellular doxorubicin concentration was found to be 0.0025 ± 0.0008 (mean ± SD) nM(-1) h(-1). The model could be used to calculate the effect of every doxorubicin concentration versus time (C-t) profile. Although in vivo parameters may well be different from those found in vitro, the model can be used to predict trends, e.g. by comparing effects of different in vivo C-t profiles.
Similar articles
-
Simulation model of doxorubicin activity in islets of human breast cancer cells.Biochim Biophys Acta. 2003 Aug 22;1622(3):169-78. doi: 10.1016/s0304-4165(03)00139-9. Biochim Biophys Acta. 2003. PMID: 12928113
-
A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.Cancer Res. 1988 Oct 1;48(19):5447-54. Cancer Res. 1988. PMID: 3046738
-
The clonogenic assay: robustness of plating efficiency-based analysis is strongly compromised by cellular cooperation.Radiat Oncol. 2020 Oct 29;15(1):248. doi: 10.1186/s13014-020-01697-y. Radiat Oncol. 2020. PMID: 33121517 Free PMC article.
-
Clonogenic and nonclonogenic in vitro chemosensitivity assays.Cancer Treat Rep. 1985 Jun;69(6):615-32. Cancer Treat Rep. 1985. PMID: 3893692 Review.
-
Analysis of clonogenic growth in vitro.Nat Protoc. 2021 Nov;16(11):4963-4991. doi: 10.1038/s41596-021-00615-0. Epub 2021 Oct 25. Nat Protoc. 2021. PMID: 34697469 Review.
Cited by
-
Three model shapes of Doxorubicin for liposome encapsulation.J Mol Model. 2014 Nov;20(11):2504. doi: 10.1007/s00894-014-2504-1. Epub 2014 Nov 6. J Mol Model. 2014. PMID: 25374391
-
Modeling cancer metabolism on a genome scale.Mol Syst Biol. 2015 Jun 30;11(6):817. doi: 10.15252/msb.20145307. Mol Syst Biol. 2015. PMID: 26130389 Free PMC article. Review.
-
Leveraging Mathematical Modeling to Quantify Pharmacokinetic and Pharmacodynamic Pathways: Equivalent Dose Metric.Front Physiol. 2019 May 22;10:616. doi: 10.3389/fphys.2019.00616. eCollection 2019. Front Physiol. 2019. PMID: 31178753 Free PMC article.
-
A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer.Sci Rep. 2017 Jul 18;7(1):5725. doi: 10.1038/s41598-017-05902-z. Sci Rep. 2017. PMID: 28720897 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical